Seres Therapeutics Announces Initiation Of Ser 287 Phase о About ser 287 ser‐287 is a biologically sourced oral capsule developed using seres’ proprietary microbiome therapeutics platform. the ser 287 phase 2b study clinicaltrials.gov identifier is nct03759041. a ser 287 phase 1b placebo controlled induction study in patients with mild to moderate active ulcerative colitis demonstrated a dose. The company continues to conduct analyses on its ser 287 and ser 301 uc clinical stage programs to inform next steps for further development. based on the ser 287 phase 2b microbiome data analyses, engraftment of ser 287 bacteria was statistically significant in patients receiving ser 287 versus placebo (p ≤ 0.001 at all timepoints).
Seres Therapeutics Announces Initiation Of Ser 287 Phase о Cambridge, mass. (business wire) jul. 22, 2021 seres therapeutics, inc. (nasdaq: mcrb), a leading microbiome therapeutics company, today announced topline results from the phase 2b eco reset study evaluating ser 287 in patients with mild to moderate ulcerative colitis (uc). the study did not meet its primary endpoint of improving clinical remission rates compared to placebo. About ser 287 ser‐287 is a biologically sourced oral capsule developed using seres’ proprietary microbiome therapeutics platform. the ser 287 phase 2b study clinicaltrials.gov identifier is. Based on the ser 287 phase 2b microbiome data analyses, engraftment of ser 287 bacteria was statistically significant in patients receiving ser 287 versus placebo (p ≤ 0.001 at all timepoints). Seres therapeutics, inc., a leading microbiome therapeutics company, today announced preliminary microbiome data analyses from the phase 2 b eco reset study evaluating ser 287 in patients with.
Comments are closed.